0001209191-21-056971.txt : 20210920
0001209191-21-056971.hdr.sgml : 20210920
20210920202038
ACCESSION NUMBER: 0001209191-21-056971
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210909
FILED AS OF DATE: 20210920
DATE AS OF CHANGE: 20210920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clem Kerry M
CENTRAL INDEX KEY: 0001883938
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31938
FILM NUMBER: 211264493
MAIL ADDRESS:
STREET 1: 420 SAW MILL RIVER ROAD
CITY: ARDSLEY
STATE: NY
ZIP: 10502
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACORDA THERAPEUTICS INC
CENTRAL INDEX KEY: 0001008848
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 420 SAW MILL RIVER ROAD
CITY: ARDSLEY
STATE: NY
ZIP: 10502
BUSINESS PHONE: 914-347-4300
MAIL ADDRESS:
STREET 1: 420 SAW MILL RIVER ROAD
CITY: ARDSLEY
STATE: NY
ZIP: 10502
3/A
1
doc3a.xml
FORM 3/A SUBMISSION
X0206
3/A
2021-09-09
2021-09-20
0
0001008848
ACORDA THERAPEUTICS INC
ACOR
0001883938
Clem Kerry M
420 SAW MILL RIVER ROAD
ARDSLEY
NY
10502
0
1
0
0
Chief Commercial Officer
Common Stock
11594
D
Employee Stock Option (right to buy)
158.10
2022-03-15
Common Stock
3000
D
Employee Stock Option (right to buy)
182.76
2023-03-06
Common Stock
3543
D
Employee Stock Option (right to buy)
236.28
2024-03-05
Common Stock
3543
D
Employee Stock Option (right to buy)
214.44
2025-03-04
Common Stock
3188
D
Employee Stock Option (right to buy)
213.18
2026-03-02
Common Stock
2159
D
Employee Stock Option (right to buy)
164.85
2027-03-01
Common Stock
1250
D
Employee Stock Option (right to buy)
146.10
2028-03-01
Common Stock
1967
D
Employee Stock Option (right to buy)
81.06
2029-03-08
Common Stock
1834
D
Employee Stock Option (right to buy)
14.46
2029-11-07
Common Stock
9168
D
Employee Stock Option (right to buy)
3.1572
2030-09-01
Common Stock
2501
D
Includes 550 unvested restricted stock awards and 6,675 unvested restricted stock unit awards issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. 275 of the restricted stock awards vest on December 1, 2021 and 275 vest on December 1, 2022, subject to continued service. The restricted stock units each represent a contingent right to one share of the Issuer's common stock, subject to continued service, vesting in installments of 20% and 40% on March 3, 2022 and September 3, 2022, respectively.
Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2016.
Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2017.
Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2018.
Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2019.
Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2020.
Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2021.
Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2019, with the first quarterly installment vesting on April 1, 2019.
Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over two years beginning on November 7, 2019, with the first quarterly installment vesting on February 7, 2020.
Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on September 1, 2020, with the first quarterly installment vesting on December 1, 2020.
This amendment is refiled due to incorrect Power of Attorney on the initial Form 3 filing.
/s/ Kerry M. Clem
2021-09-20
EX-24.3A_1009318
2
poa.txt
POA DOCUMENT
LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS
Exhibit 24 - POWER OF ATTORNEY
For Executing Forms 3, 4 and 5
Know all by these presents, that the undersigned hereby constitutes and
appoints each of Ron Cohen and Andrew Mayer or any of them acting singly, and
with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:
1. prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC"), a Form ID,
including any amendments thereto, and any other documents necessary or
appropriate to obtain codes and passwords enabling the undersigned to make
electronic filings with the SEC of reports required by Section 16(a) of the
Securities Exchange Act of 1934 or any rule or regulation of the SEC;
2. prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the SEC, Forms 3, 4 and 5, and any amendments thereto, in
accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;
3. do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and file such form
with the SEC and any stock exchange or similar authority; and
4. take any other action of any type whatsoever in connection with the foregoing
which, in the opinion of such attorney-in-fact, may be of benefit to, in the
interest of, or legally required by, the undersigned, it being understood that
the documents executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power of Attorney shall be in such form and shall contain such
terms and conditions as such attorney-in-fact may approve in his/her discretion.
The undersigned hereby grants to each attorney-in- fact full power and
authority to do and perform all and every act and thing whatsoever requisite,
necessary and proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or his/her
substitute or substitutes, shall lawfully do or cause to be done by virtue of
this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is Acorda
Therapeutics, Inc. assuming, any of the undersigned's responsibilities to comply
with Section 16(a) of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by Acorda
Therapeutics, Inc., unless earlier revoked by the undersigned in a signed
writing delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 9 day of September 2021.
/s/ Kerry M. Clem
__________________________________
Kerry Clem
Notary Signature & Seal to be Placed Here:
Lim Kim A.
Notary Public, State of New York
No. 01L16144154
Qualified in Westchester County
Commission Expires Apr. 24, 2022